Does Corneal Collagen Cross-linking Reduce the Need for Keratoplasties in Patients With Keratoconus?. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Sandvik, Gunhild Falleth; Thorsrud, Andreas; Råen, Marianne; Østern, Atle E.; Sæthre, Marit; Drolsum, Liv
• Is Part Of: Cornea. Volume 34:Issue 9(2015)
• Publication Date: 2015-09
• Subjects: keratoconus -- corneal collagen cross-linking -- keratoplasty; Cornea -- Periodicals; Cornea -- Periodicals; Cornée -- Périodiques; 617.719
• DOI: 10.1097/ICO.0000000000000460
• Languages: English
• ISSNs: 0277-3740

Abstract

Abstract : Purpose: To investigate whether the introduction of corneal collagen cross-linking (CXL) influences the frequency of keratoplasties in patients with keratoconus. Methods: Data were obtained from a cohort of patients from our corneal transplant registry. Two different periods were compared, 2005 to 2006 (period 1) and 2013 to 2014 (period 2). Patients during period 1 had surgery before the introduction of CXL treatment, and patients in period 2 had surgery after this treatment was well established in our department. Age and gender were registered, and the Amsler–Krumeich classification system was applied to grade the degree of keratoconus. Results: The total number of keratoplasties performed during period 1 was 137, and keratoconus was the cause of surgery in 55 eyes (55 patients). The corresponding numbers in period 2 were 231 and 26 eyes (26 patients), respectively. The difference in the number of keratoplasties for keratoconus in both periods was statistically significant ( P = 0.003). There were no significant differences in the distributions of age and gender between both periods. In period 1, 63.6% of the eyes were graded as stage 4 in the Amsler–Krumeich classification, compared with 96.2% in period 2 ( P = 0.001). Conclusions: The frequency of keratoplasty for keratoconus has been more than halved in our department over the last decade. There is reason to believe that this reduction is for a great part caused by the introduction of CXL treatment.